Education
About Us
Working with TipRanks
Follow Us
Dov Elefant Insider Profile
4 Followers
Dov Elefant, CFO at Akari Therapeutics, holds 0.00 shares in Akari Therapeutics (Ticker: AKTX), holds 4.35K shares in Cellectar Biosciences (Ticker: CLRB), holds 0.00 shares in Immune Pharmaceuticals (Ticker: IMNPQ). Most recently, Dov Elefant ― shares of Akari Therapeutics on ― for an estimated value of ―.
Dov Elefant has not reported sufficient informative transactions and therefore cannot be ranked.
Time Frame
Compare to
Insider Holdings
Insider Roles
Roles that Dov Elefant holds in companies
Most Profitable Insider Trade
Currently, no data available
The most profitable trade made by Dov Elefant
Dov Elefant's Trading History
Akari Therapeutics
―
CFO
―
$0.00
Cellectar Biosciences
Jun 08, 2020
CFO
Informative Buy
4.96K
$5.35K
Immune Pharmaceuticals
―
Controller - VP - Fin & Admin
―
$0.00
List of latest transactions for each holding click on a transaction to see Dov Elefant's performance on stock
You May Also Like
Dov Elefant insider profile FAQ
What is the percentage of profitable transactions made by Dov Elefant?
The percentage of profitable transactions made by Dov Elefant is ―.
What is the average return per transaction made by Dov Elefant?
The average return per transaction made by Dov Elefant is ―.
What stocks does Dov Elefant hold?
Dov Elefant holds: AKTX, CLRB, IMNPQ stocks.
What was Dov Elefant’s latest transaction?
Dov Elefant latest transaction was an Uninformative Buy of ―.
What was Dov Elefant's most profitable transaction?
Dov Elefant’s most profitable transaction was an Uninformative Buy of stock on ―. The return on the trade was ―.
What is Dov Elefant's role in Akari Therapeutics?
Dov Elefant's role in Akari Therapeutics is CFO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.